Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients
- 1 August 2001
- journal article
- clinical trial
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 95 (2) , 213-221
- https://doi.org/10.3171/jns.2001.95.2.0213
Abstract
Object. A blinded evaluation of the effects of subthalamic nucleus (STN) stimulation was performed in levodopaintolerant patients with Parkinson disease (PD). These patients (Group I, seven patients) were moderately or severely disabled (Hoehn and Yahr Stages III–V during the off period), but were receiving only a small dose of medication (levodopa-equivalent dose [LED] 0–400 mg/day) because they suffered unbearable side effects. The results were analyzed in comparison with those obtained in patients with advanced PD (Group II, seven patients) who were severely disabled (Hoehn and Yahr Stages IV and V during the off period), but were treated with a large dose of medication (500–990 mg/day). Methods. The patients were evaluated twice at 6 to 8 months after surgery. To determine the actual benefits afforded by STN stimulation to their overall daily activities, the patients were maintained on their medication regimen with optimal doses and schedules. Stimulation was turned off overnight for at least 12 hours...Keywords
This publication has 36 references indexed in Scilit:
- High frequency stimulation of the subthalamic nucleus and levodopa induced dyskinesias in Parkinson's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2000
- Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulationMovement Disorders, 1998
- Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's diseaseAnnals of Neurology, 1998
- Control of Poststroke Involuntary and Voluntary Movement Disorders with Deep Brain or Epidural Cortical StimulationStereotactic and Functional Neurosurgery, 1997
- Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.Journal of Clinical Investigation, 1995
- A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's diseaseMovement Disorders, 1994
- Acute and Long-Term Effects of Subthalamic Nucleus Stimulation in Parkinson's DiseaseStereotactic and Functional Neurosurgery, 1994
- L-DOPA reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatumJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1985
- Levodopa and Decarboxylase InhibitorsDrugs, 1976
- ParkinsonismNeurology, 1967